Study identifier:SA-NXY-0008
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A single-center phase I study in healthy, male volunteers, consisting of two separate randomized, double-blind, placebo controlled three-period cross-over sessions assessing the effect of NXY-059 (8 h i.v. infusion) on bleeding time, platelet aggregation and platelet adhesion as compared with that of desmopressin (10 min i.v. injection) and ASA (160 mg o.d. for three days) respectively
Stroke
Phase 1
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
-
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|